E.R.R

E.R.R

Wednesday, December 17, 2014

FIGHT PROSTATE CANCER NOW BY HEEDING SOYINKA’S ADMONITION / AN ASPIRIN A DAY TO KEEP THE PROSTATE CANCER AT BAY?




n December of 2010, I visited Nigeria and on Christmas day attended morning service at my church in my hometown. Service had already started when we arrived at the church grounds. As I hurriedly made my way towards the building entrance, my eyes momentarily settled on a man that was standing on the far end of the steps that led up to the foyer under the bell tower. My eyes were about to wander away from him when it dawned on me that something about him seemed familiar. It took casting a steady gaze on him for a few more seconds for me to realize that he was an elementary school classmate of mine that I saw last more than 30 years earlier. For the sake of privacy, I will call him Chuma. I walked up to him and as soon as he recognized me, he smiled and stuck out his hand in greeting. I shook his hand. “Unu anatalu?”, - “did you guys return?” he asked smiling. Yes I said sizing him up. I was surprised that he grew taller and bigger than I would have imagined when we were all playing soccer and climbing all imaginable trees in my neighborhood many years earlier. After exchange of pleasantries, I left him and went into the church.
The thought of meeting him after so many years did not leave my mind but there was something unusual about the meeting. His smile seemed forced and even somewhat pained. I had expected a more boisterous greeting on both sides and was poised to set the pace but when I sensed that he seemed reserved, I pulled back and settled with the hand shake he seemed to prefer. I eventually concluded that his reserved disposition was the result of the fact that after many years of not seeing each other, we had in so many ways become strangers to one another. Our interests had diverged so much that we did not have much to discuss except to ask about our families.
A few weeks later, I was back in the States after the Christmas vacation. The reader can imagine my shock when I later heard, I am not exactly sure how long later, that he had passed away! “What happened?,” I had asked in bewilderment when I was told of his passing. “I just saw this guy the Christmas of 2010”, I had said to the guy breaking the bad news to me. “He started having constant pain around his waist”, the man had told me, “and when he visited the doctor, he was told that the waist pain was attributable to the fact that as transporter, he was always sitting in the car and embarking on long distance drives”. Of course he had other symptoms but the waist pain was said to be more pronounced and lingered. Later he fell sicker and sicker and that was when they discovered that he had prostate cancer before he eventually passed away. I could not believe what I was hearing. Apparently, he was already experiencing the many symptoms of the disease when I saw him at church and it could have been the reason for his seeming “pained” smile and reserved disposition. I was very sad that a young man had been taken away at the prime of his existence.
It was with this in mind that I read the interview where Professor Wole Soyinka revealed that he had become a prostate cancer survivor. He followed his revelation with an admonition to the federal government to establish cancer-screening clinics in Nigeria. In line with Soyinka’s classy way of doing things, instead of hiding his diagnosis as many Nigerians would do, he spoke up about it and used his clout to ask the government to do something about it. I was hoping that many more prominent Nigerians will join his call but of course since it does not involve sharing of money, they will not speak up in support of Soyinka’s prescription.
Chuma’s case is not the first time I have had to contend with the news of someone I know suffering from the ailment or even dying. Infact, the number of people I know that are living with the disease is so staggering that one is tempted to believe that it has become one of the most common but deadly diseases in Nigeria for men. When I visited Nigeria in 2007, a friend told me the story of his contemporary that had undergone prostate cancer surgery in the country. The surgery had gone wrong and all manners of complications had developed. I was almost moved to tears as the story was narrated of what a once boisterous and ebullient man was going through including loss of appetite for existence. I began to wonder if the doctor that performed the operation was even trained to do so or whether he even fully understood how the disease worked before embarking on the operation. Up to this date, I have not mastered the gumption to ask how things eventually turned out for the man. I am always hoping and praying silently that the day I ever toughen up to ask, I will be told that he beat the disease. Now, just a few weeks ago, I got the sad news that a relative had passed away as a result of the disease. I am still trying to process the news of my relative’s passing.
In all, prostate cancer is real. It is said to be the number four killer of men worldwide. It can be deadly if not detected early but the good news is that early detection has proven to be the key to survival. If detected early, it can be cured fully through a combination of surgery and therapy and the patient will live a full and productive life. Just here in the United States, high profile personalities like John Kerry and Colin Powel are good examples of survivors that are living normal lives because their cases were detected early and treated.
I will never forget what happened in my doctor’s office when I turned 50 and visited my doctor for routine yearly physical. After conducting the rest of the physicals, my doctor said, “now that you have turned 50, there are two screening tests that you will now be subjected to every year you show up for your physical. The goal of the test is to ensure that your prostate is working well” “It is recommended for every male 50 years and over”, he continued, “but could start earlier for those with genetic disposition for prostate cancer”. I knew what the test was from stories of older contemporaries and had long dreaded being subjected to it but at this moment, I had to do what my doctor said; I had no choice. “It is a two part test”, he continued, “one of the tests will be done here in the office and the other will be done using your blood in the lab”. “Ok”, I answered, already feeling embarrassed but trying to hide my emotions. “I will caution you”, he said further while scribbling some notes on a pad in front of him, “that the one that will be done here can be uncomfortable”. With that, he asked that I turn around! The bottom line is that I did not like having someone probe my rear yet it was a life-saving necessary evil. The screening is a procedure that would tell the doctor whether the prostate has started enlarging beyond normal levels or if lumps of any sort had developed that would warrant attention. Any reader that wants more information on how the office screening is done could google it.
This test was followed up in the lab with a blood test called PSA or prostate specific antigen. The presence of the antigen in the blood in certain amounts provide indication of whether the prostate had become diseased especially with cancer. Most survivors of prostate cancer are men that their doctors became alerted of the disease through a combination of this test and the rear “body cavity” probing. Of course some had already developed symptoms like constant and burning urination and the sorts but the bottom line is that early detection made the difference between survival and death.
My classmate Chuma may not have died had his disease been detected early. He only went to a doctor when the symptoms had started manifesting. Yet, most probably, the disease developed and progressed years before he became symptomatic with waist pain, constant urination and the rest. It is possible that yearly physicals capped with PSA blood tests would have detected the disease early and his life saved but that is water under the bridge now for Chuma. A young man with children that depended on him not just for subsistence but for guidance, has passed away, leaving broken hopes and shattered dreams. He also left a young widow to fend for the children. The living must now learn from that experience and begin to take control of their health through proactive yearly physicals that must include these tests.
Nigeria must heed Wole Soyinka’s admonition and begin to establish, as a priority, more cancer screening clinics and testing labs all over. Also, there has to be a regulatory body that oversees what these testing labs do as it is my considered opinion that some are not fit to be in business. I have seen situations where lab test results seem to vary depending on where they were done. Sometimes, false positives or false negatives result, confusing doctors into making the wrong diagnoses. Furthermore, there has to be a way to bring down the costs of these tests to a level that the common Nigerian can afford. Everything costs in the thousands in the country and such situations may be contributing to the aversion of some people to going to the labs or seeing doctors regularly.
When I saw Wole Soyinka’s interview, I decided to write about this with the hope that the average Nigerian reading this will become more sensitized to take action now. As the Igbo would say, “tata bu gboo” “today is early”.



May God Help Us


HERE I STAND!

Tuesday, December 16, 2014


Alfred Obiora Uzokwe, P.E
.................................................................................................................

AN ASPIRIN A DAY TO KEEP THE PROSTATE CANCER AT BAY?

By Dr. Jennifer R. Rider

PCF Young Investigator, Dr. Jennifer R. Rider of Brigham and Women’s Hospital and the Harvard School of Public Health looks into what impact aspirin therapy might have on prostate cancer. (Video) Also, Questions to Ask your Doctor Regarding Aspirin Use, and this admonition: please, don’t self-treat

January 10, 2013 -- Aspirin, or acetylsalicylic acid, is an elegant drug used since the 19th century to relieve pain and reduce fever and inflammation. (Long before there was Bayer, ancient peoples medicated themselves with the natural form of salicylic acid found in plants.) Aspirin also simultaneously functions as an anticoagulant, thinning our blood and reducing the risk of clot formation. Thus, apart from easing our aches and pains, aspirin can also be used to prevent heart attacks and strokes. To add to its appeal, aspirin is cheap and can easily be accessed by most people in the world. All of these potential benefits do not come without some risk, as aspirin has potentially serious side effects such as gastrointestinal bleeding caused by its blood thinning properties and may actually induce hemorrhagic stroke if high doses prevent necessary clotting from occurring. But on the whole, aspirin has made the world an easier place for humans to live. And now there is tantalizing evidence of another use for aspirin: as a chemo-preventive agent against cancer.
In multiple observational studies of aspirin use—studies in which the real-world aspirin-taking behaviors of individuals are observed, recorded and related to outcome—aspirin is consistently associated with a reduced risk of various cancers, including cancers of the colon/rectum, esophagus, liver, and breast. The strongest associations are typically seen for gastrointestinal tumors, with a 40-50% reduction in risk of colorectal cancer associated with daily aspirin use. Observational studies give less definitive results than gold standard, randomized studies. However, when researchers compared observational studies of aspirin use and cancer risk and outcomes to randomized trials that assigned study participants to either aspirin or placebo, they found a high level of correlation of the findings. (Algra AM and Rothwell PM, Lancet 2012;13:518-27).
Especially encouraging, regular aspirin use is frequently associated with a lower risk of cancer spreading, or metastasizing to distant sites. In a pooled analysis of five large randomized trials of daily aspirin use (Rothwell et al, Lancet 2012;379:1591-601), aspirin treatment was associated with an approximately 35% reduction in risk of any cancer with distant metastasis. For patients diagnosed with a form of cancer known as adenocarcinoma (prostate cancer is almost always an adenocarcinoma, as are the majority of breast, uterine, and colon cancers), regular aspirin use decreased their risk of cancer spread by 50%. And among those with adenocarcinoma, aspirin treatment reduced risk of cancer death by half among those without distant metastases at diagnosis and by 35% among trial participants overall. Men and women of all ages appeared to benefit, and the benefit could be obtained even with low-dose aspirin, which is less likely to produce side effects.

Listen as Dr. Rider summarizes this article on aspirin use and prostate cancer risk and progression.

Aspirin use generally linked to lower risks of developing prostate cancer

Several population-based, observational studies have demonstrated that regular aspirin use is associated with a modestly lower incidence of prostate cancer. For instance, among a population of more than 29,000 men in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial (PLCO), taking at least one aspirin pill per day was associated with a modest but statistically significant 8% reduction in risk of prostate cancer (Shebl FM et al. BMJ 2012;107:207-14). Men over 65 realized the most gain, with a 13% reduced risk of developing prostate cancer. Interestingly, no association was observed in this population for ibuprofen. That is, in the population of men observed in this study, taking ibuprofen didn’t lower men’s risk of developing prostate cancer.
The American Cancer Society’s Cancer Prevention Study II Nutrition Cohort (Jacobs EJ et al, JNCI 2005;97:975-80) looked at a wide range of drugs classified as non-steroidal anti-inflammatories (NSAIDs) such as aspirin, ibuprofen and naproxen, and found no association with current NSAID use at any dosage level. However, long-term, regular use (30 or more pills per month for five or more years) was associated with an 18% reduction in risk of developing prostate cancer; when broken out for long-term aspirin use alone, they found a 15% reduction in risk.
A study of prescription records from the United Kingdom showed that having a current prescription for aspirin was associated with a 30% lower risk of prostate cancer. Another study of pharmacy records of patients in Quebec found a similarly reduced risk of prostate cancer for long-time aspirin users. Also, a study of health plan members of Kaiser Permanente in California reported a 20% reduction in risk for aspirin users of six or more pills per day.
And a more recent analysis of long-term aspirin use and prostate cancer risk published in 2011 in the International Journal of Cancer (Dhillon et al, Int J Cancer 2011;128:2442-52),followed men in the Health Professionals Follow-up Study. This particular study, which included 18 years of follow-up and nearly 5,000 prostate cancer cases, found that the use of at least two regular strength aspirin pills per week was associated with a 10% reduction in total risk for prostate cancer. Perhaps more importantly, taking at least six tablets per week was associated with a nearly 30% reduction of both high-grade prostate cancer and lethal disease.
Yet, not all studies demonstrate a potential benefit from aspirin use for either aggressive or overall prostate cancer risk. A large population-based study in Sweden that included 29,770 prostate cancer cases found no association with low-dose aspirin use in the year prior to diagnosis and aggressiveness of the cancer, as indicated by stage and tumor grade at the time of diagnosis. (Jonsson F et al. Br J Cancer 2013; Epub online). And, in the ProtecT study (Murad AS et al, Int J Cancer 2011;128;1442-8), a UK-based case-control study, use of all NSAIDs was associated with a 25% statistically significant increase in risk of total prostate cancer. However, a more modest 13% increase in risk, associated with aspirin use specifically, was not statistically significant.

No comments: